B2RLaw advised Life Science Innovation Fund on its investment in a healthtech startup
B2RLaw has advised the Life Science Innovation Fund on its investment in AIDLAB, a telemedical startup. The aim of the investment is to develop a new product, AIDMED, a device which remotely diagnoses diseases, particularly sleep breathing and cardiac disorders.
The healthtech industry is experiencing noticeable growth during the current pandemic. Innovative solutions that allow certain activities to be performed remotely are relieving the burden on medical personnel while providing more comfortable conditions for patients. AIDMED’s solutions can reduce hospitalization periods to a minimum using artificial intelligence to analyze measurements.
The investor is a Polish VC, Life Science Innovation Fund, which invests in MedTech, Biotech and Health Care, and has invested in a number of successful companies such as BrainScan, Bioseco, LumiSep and LifeFlow.
B2RLaw’s consisted of Partner Szymon Syp, Ph.D. and Senior Associate Iga Wojtczak-Opala.
View more resources
Catch up on the very latest B2RLAW
announcements and news here.
We are pleased to advise that B2RLaw has been short-listed by the prestigious international legal magazine with the largest global […]
In its first full three months since announcing its merger on 21st June 2020, B2RLaw has been ranked by Pitchbook […]
B2RLaw advised the founders of WalkSee sp.z o.o. on an investment made by EVIG Alfa Venture Capital into the company. […]
With growing client demand and a fast changing environment, B2RLaw has launched one of the first cannabis practices on the […]
B2RLaw has advised the Life Science Innovation Fund on its investment in AIDLAB, a telemedical startup. The aim of the […]
B2RLaw advised Apis Venture sp. z o.o., a venture capital fund from Warsaw, with regards its investment in Byte Barrel […]
Get in touch
Not sure who to contact? Let us help you find the right lawyer.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.